Phase 3 trial results show roflumilast cream 0.05% to be a safe and effective treatment for children with atopic dermatitis.

Once-daily roflumilast cream 0.05 percent is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 ye ...

Once-daily roflumilast cream 0.05% is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according to a study published online Feb. 20 in Pediatric Dermatology.

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

AlphaQuest LLC lessened its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 83.3% in the ...

Arcutis Biotherapeutics, Inc.’s ARQT share price has surged by 12.31%, which has investors questioning if this is right time to sell.

Bank of New York Mellon Corp decreased its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 1.9% in the 4th quarter, according to its most recent Form 13F filing with the ...

Two months later, Arcutis won approval for its Zoryve (roflumilast) cream. Both are once-a-day treatments. For moderate to severe cases, systemic biologics work to suppress the immune system and ...

The FDA had been due to give its verdict on the Zoryve (roflumilast) for the new use on the 7th of this month, but the date came and went. In an unusual attempt to quell shareholder jitters ...